<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25195125</article-id><article-id pub-id-type="pmc">4162914</article-id><article-id pub-id-type="publisher-id">2220</article-id><article-id pub-id-type="doi">10.1186/1745-6215-15-352</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarction: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rudd</surname><given-names>Nima</given-names></name><address><email>nima.rudd@nh.org.au</email></address><xref ref-type="aff" rid="Aff16"/><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Subiakto</surname><given-names>Ivan</given-names></name><address><email>ivansubiakto@gmail.com</email></address><xref ref-type="aff" rid="Aff16"/><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Asrar ul Haq</surname><given-names>Muhammad</given-names></name><address><email>Muhammad.asrar@unimelb.edu.au</email></address><xref ref-type="aff" rid="Aff16"/><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Mutha</surname><given-names>Vivek</given-names></name><address><email>vivekm@me.com</email></address><xref ref-type="aff" rid="Aff16"/><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Van Gaal</surname><given-names>William J</given-names></name><address><email>William.vanGaal@nh.org.au</email></address><xref ref-type="aff" rid="Aff16"/><xref ref-type="aff" rid="Aff17"/></contrib><aff id="Aff16"><label/>Department of Cardiology, The Northern Hospital, 185 Cooper Street, Epping, 3076 VIC Australia </aff><aff id="Aff17"><label/>Department of Medicine, University of Melbourne, Grattan St, Melbourne, 2010 VIC Australia </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>15</volume><elocation-id>352</elocation-id><history><date date-type="received"><day>30</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Rudd et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The incidence of perioperative myocardial infarction (PMI) globally is known to be around 2 to 3% and can prolong hospitalization, increased morbidity and mortality. Little is known about the pathophysiology and risk factors for PMI. We investigate the presence of elevated novel cardiac markers and preoperative coronary artery plaque through contemporary laboratory techniques to determine the correlation with PMI, as well as studying ivabradine and atorvastatin as protective pharmacotherapies against PMI in the context of orthopedic surgery.</p></sec><sec><title>Methods/Design</title><p>We aim to enroll 200 patients aged above 60&#x000a0;years who suffer from neck of femur fracture requiring surgery. Patients will be randomized to four arms (no study drugs, atorvastatin only, ivabradine only and ivabradine and atorvastatin). Our primary outcome is incidence of PMI. All patients will receive an electrocardiogram, cardiac echocardiography, measurement of novel cardiac biomarkers and computed tomography (CT) coronary angiography. A telephone interview post discharge will be conducted at 30&#x000a0;days, 60&#x000a0;days and 1&#x000a0;year.</p></sec><sec><title>Discussion</title><p>We postulate that ivabradine and atorvastatin will reduce the rate and magnitude of PMI following surgery by reducing heart rate and attenuating catecholamine-induced tachycardia postoperatively. Secondly, we postulate that postoperative reduction in heart rate and catecholamine-induced tachycardia with ivabradine will correlate with a reduction in cardiovascular novel biomarkers which will reduce atrial stretch and postoperative incidence of arrhythmia. We aim to demonstrate that treatment with ivabradine and atorvastatin will cause a reduction in the incidence and magnitude of PMI, the benefit of which is derived primarily in patients with greater atherosclerotic burden as measured by higher CT coronary calcium scores.</p></sec><sec><title>Trial registration</title><p>This study protocol has been listed in the Australia New Zealand Clinical Trial Registry (registration number: <ext-link ext-link-type="uri" xlink:href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000340831">ACTRN12612000340831</ext-link>) on 23 March 2012.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ivabradine</kwd><kwd>Perioperative myocardial infarction</kwd><kwd>Atorvastatin</kwd><kwd>Computed tomography coronary plaque</kwd><kwd>Novel biomarkers</kwd><kwd>Lipid metabolism</kwd><kwd>Postoperative arrhythmia</kwd><kwd>Coronary artery disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>In the United States approximately 24 million surgical procedures are performed annually [<xref ref-type="bibr" rid="CR1">1</xref>], and it is estimated that 1 million of these operations will be complicated by a perioperative cardiovascular event [<xref ref-type="bibr" rid="CR2">2</xref>]. With more than 230 million major surgical operations being performed every year worldwide, the scope of this problem is massive [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Among patients undergoing major non-cardiac surgery, the overall incidence of perioperative myocardial infarction (PMI) is 2 to 3%, and in higher risk populations, such as those patients undergoing vascular surgery, rates can be as high as 34% globally [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. PMI is clinically a very significant occurrence, associated with prolonged hospital stay, substantial morbidity and mortality rates as high as 25 to 40% [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p>The definition of PMI is based on the recent universal definition and requires a rise and fall of cardiac biomarkers (preferably troponin), with at least one measurement above the 99th percentile of the upper reference limit, in the setting of either symptoms of ischemia, electrocardiogram (ECG) changes or imaging evidence of necrosis [<xref ref-type="bibr" rid="CR8">8</xref>]. However, the majority of postoperative troponin elevations are asymptomatic, without ECG or imaging evidence of infarction, yet still confer a substantially increased risk of death [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. As such, the distinction between infarction and necrosis is often subtle, and many patients will not meet the criteria for infarction simply based on the absence of routine postoperative cardiac imaging. Furthermore, small myocardial infarcts usually do not produce wall motion abnormalities on an echocardiogram., As such, imaging evidence of small infarcts will rely on cardiac magnetic resonance imaging [<xref ref-type="bibr" rid="CR12">12</xref>], a technique which is often impractical in the postoperative period and is certainly not routine.</p><p>In a previous study of patients undergoing urgent orthopedic surgery, PMI, as defined by troponin I elevation, occurred in 52.9% of patients. The majority of biomarker elevations in these patients were asymptomatic, with only 9.8% of patients meeting the universal definition criteria for myocardial infarction. Whilst patients within each quartile of troponin elevation demonstrated increasing mortality at 12&#x000a0;months, mortality was dramatically increased across the board in those with any postoperative troponin elevation (37% versus 2.1%, <italic>P</italic> &#x0003c;0.0001) [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>We subsequently performed an intervention study of patients with troponin elevation following emergent surgery for fractured neck of femur (NOF), and randomized patients to standard care or referral to the cardiology unit [<xref ref-type="bibr" rid="CR14">14</xref>]. The main intervention by the cardiology unit was commencement of aspirin and beta-blockers, however this made no difference in mortality at follow-up. The study did confirm the high rate of troponin elevation in this group, and again confirmed the increased mortality conferred by postoperative troponin increase. It may be that efforts to prevent PMI will be more successful in improving outcomes following surgery rather than postoperative interventions directed at patients with PMI.</p><p>The exact mechanisms of PMI are not well understood, however two broad theories are postulated; myocardial stress and plaque rupture [<xref ref-type="bibr" rid="CR15">15</xref>]. Prevention of myocardial stress and/or plaque rupture may reduce the incidence of PMI and therefore have been the subject of multiple studies.</p><sec id="Sec2"><title>Myocardial stress (myocardial oxygen supply-demand imbalance) and role of ivabradine</title><p>Studies suggest that tachycardia is the most common cause of postoperative oxygen supply-demand imbalance leading to PMI [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Numerous studies using perioperative Holter monitoring in patients undergoing major surgery have shown that asymptomatic, heart rate related ST segment depression is common postoperatively and associated with in-hospital [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] and long-term morbidity and mortality [<xref ref-type="bibr" rid="CR20">20</xref>]. Postoperative cardiac complications, including sudden death, occur after prolonged silent ST segment depression [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Furthermore, peak troponin elevation correlates with the duration of ST segment depression [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>These studies are the basis for trials examining the use of perioperative beta-blockers to reduce the incidence of postoperative cardiac events. Initial small studies were promising [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], however other moderate-sized randomized trials failed to show benefit [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. A subsequent meta-analysis of non-cardiac surgery randomized controlled trials did suggest a benefit for beta-blockers in the reduction of cardiovascular events, but showed an increased risk of hypotension and bradycardia [<xref ref-type="bibr" rid="CR29">29</xref>]. The largest randomized controlled trial to date, the POISE trial (Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery), randomized 8,351 patients at increased risk of cardiovascular events to receive metoprolol or placebo [<xref ref-type="bibr" rid="CR30">30</xref>]. The group assigned to metoprolol showed a reduction in myocardial infarction (4.2 versus 5.7%, <italic>P</italic>&#x02009;=&#x02009;0.002), however there was an increase rate of stroke (1.0 versus 0.5%, <italic>P</italic>&#x02009;=&#x02009;0.005) and death (3.1 versus 2.3%, <italic>P</italic>&#x02009;=&#x02009;0.03) in the treatment group. Clinically significant hypotension occurred in 625 patients (15%) in the metoprolol group. This higher incidence of clinically significant hypotension has been postulated as the cause for the occurrence of more strokes and deaths.</p><p>Postoperative atrial fibrillation (AF) is common both after cardiothoracic and non-cardiothoracic surgery [<xref ref-type="bibr" rid="CR31">31</xref>]. In patients undergoing non-cardiothoracic surgery, the reported incidence of postoperative AF is as high as 12% [<xref ref-type="bibr" rid="CR32">32</xref>], and has not been documented in an emergent orthopedic surgery group where the incidence may be higher given the typically elderly population. Postoperative AF can be observed throughout the postoperative course, with a peak on the second postoperative day [<xref ref-type="bibr" rid="CR33">33</xref>]. Even though postoperative AF can be self-limiting, it may be associated with hemodynamic derangements, postoperative stroke, PMI, ventricular arrhythmias and heart failure [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. In many reports, development of postoperative AF is associated with a longer hospital stay, greater morbidity and mortality and increased costs [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The pathophysiology of postoperative AF is not well understood, however right atrial overdistension and myocardial stretch in response to catecholamine release may play a significant role [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>Ivabradine (Coralan&#x02122;) is an orally bioavailable, specific inhibitor of the I<sub><italic>f</italic></sub> current in the sinoatrial node [<xref ref-type="bibr" rid="CR38">38</xref>]. It is a pure heart rate lowering agent in patients with sinus rhythm, but unlike beta-blockers it has no effect on blood pressure [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], myocardial contractility [<xref ref-type="bibr" rid="CR41">41</xref>], intracardiac conduction or ventricular repolarization [<xref ref-type="bibr" rid="CR42">42</xref>]. Ivabradine could potentially provide the perioperative benefits of beta-blockers without the detrimental effects of hypotension, leading to improved outcomes and reduced adverse cardiovascular events in the postoperative period. A small series case study of 15 patients showed that ivabradine does attenuate catecholamine induced tachycardia following cardiac surgery, with positive effects on cardiac index, stroke volume index and mean arterial pressure [<xref ref-type="bibr" rid="CR43">43</xref>]. A small (n&#x02009;=&#x02009;111) non-randomized study of ivabradine in patients undergoing carotid endarterectomy found that ivabradine therapy (n&#x02009;=&#x02009;33) reduced PMI compared to patients not receiving any beta-blockers or ivabradine [<xref ref-type="bibr" rid="CR44">44</xref>]. No randomized studies with ivabradine in patients undergoing cardiac or non-cardiac surgery have been performed to date.</p></sec><sec id="Sec3"><title>Acute coronary syndromes and role of atorvastatin</title><p>An acute coronary syndrome occurs when an unstable or vulnerable plaque undergoes spontaneous rupture, fissuring or erosion, leading to acute coronary thrombosis, ischemia and infarction. Although it is accepted that intraplaque inflammation plays a pivotal role in plaque instability and spontaneous acute coronary syndrome [<xref ref-type="bibr" rid="CR45">45</xref>], external stressors such as those occurring postoperatively are also believed to contribute [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], especially in patients with vulnerable plaque characterized by a thin fibrous cap [<xref ref-type="bibr" rid="CR18">18</xref>]. Indeed, the majority of perioperative troponin elevations occur in patients with underlying coronary artery disease (CAD) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Hormones that increase cardiovascular stress, such catecholamines and cortisol, increase after surgery and may remain elevated for days [<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. Elevation in plasma catecholamines correlates with postoperative cardiac troponin elevations [<xref ref-type="bibr" rid="CR50">50</xref>] and with graft occlusion after vascular surgery [<xref ref-type="bibr" rid="CR51">51</xref>]. Whilst myocardial oxygen supply-demand may be the predominant mechanism of injury, this remains unproven. The cardiovascular tension and shear stress induced by hemodynamic changes as a result of catecholamine increase may also induce plaque rupture or erosion leading to acute coronary thrombosis, ischemia and infarction. Increased platelet reactivity in the postoperative period may also be a significant contributor to plaque events leading to PMI [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p>Atorvastatin (40&#x000a0;mg orally daily) administered for seven days prior to percutaneous coronary intervention (PCI) reduces the incidence of PMI [<xref ref-type="bibr" rid="CR53">53</xref>]. It has subsequently been shown that even a single high dose (80&#x000a0;mg) of atorvastatin within 24&#x000a0;hours prior to PCI significantly lowers the overall incidence of myocardial infarction not limited only to PMI rate [<xref ref-type="bibr" rid="CR54">54</xref>].</p><p>A retrospective cohort study of 780,591 patients who underwent major non-cardiac surgery and who received statin therapy during the first two hospital days showed a reduction in crude and adjusted mortality in the statin group [<xref ref-type="bibr" rid="CR55">55</xref>]. The authors concluded that &#x02018;treatment with lipid-lowering agents may reduce risk of death following major non-cardiac surgery. Clinical trials are required to confirm this observation&#x02019;. A subsequent review showed reduced death for statin therapy in cardiac and vascular surgery, but reported no randomized trials of statin therapy in non-cardiovascular surgery [<xref ref-type="bibr" rid="CR56">56</xref>].</p></sec><sec id="Sec4"><title>Novel cardiac biomarkers</title><p>Elevated levels of circulating biomarkers related to cardiac volume, pressure overload and cardiovascular stress offer insights into subclinical cardiac stress and thus have the potential to aid in risk stratification and provide mechanistic data on disease prevention measures [<xref ref-type="bibr" rid="CR57">57</xref>]. Specifically, B-type natriuretic peptide (BNP; either the hormone or the aminoterminal fragment of the prohormone (NT-proBNP)) is a counter-regulatory hormone released predominantly from ventricular myocytes in response to ventricular dysfunction, stretching, increased wall tension and ischemia. Elevated levels of BNP have been shown to predict mortality and heart failure events across a broad range of individuals, ranging from the general population to patients with coronary disease or heart failure [<xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>]. We recently showed that elevated NT-proBNP levels pre- and postoperatively are independent predictors of in-hospital cardiac events and two-year mortality [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p>Development of newer assays that target more stable epitopes of hormones or prohormones that are released in relation to cardiomyocyte and/or vascular stress offers the potential for more refined risk assessment [<xref ref-type="bibr" rid="CR65">65</xref>]. Specifically, atrial natriuretic peptide (ANP) is a vasodilator and natriuretic that is synthesized in the myocardium in response to increased wall tension [<xref ref-type="bibr" rid="CR66">66</xref>]. Adrenomedullin (ADM) is a potent vasodilator synthesized in the adrenal medulla, vascular endothelial cells, heart and elsewhere in response to physical stretch and specific cytokines, with levels in the heart elevated in the setting of pressure and volume overload [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Endothelin-1 (ET-1) is a potent vasoconstrictor and profibrotic hormone that is secreted by vascular endothelial cells, with levels correlating with shear stress and pulmonary artery pressure [<xref ref-type="bibr" rid="CR69">69</xref>]. In patients with stable coronary artery disease and preserved left ventricular ejection fraction, elevated levels of these novel biomarkers can help identify patients who are at higher risk of cardiovascular death and heart failure [<xref ref-type="bibr" rid="CR65">65</xref>]. Higher levels of these three biomarkers have been associated with an increased risk of death and/or heart failure events in patients with established heart failure [<xref ref-type="bibr" rid="CR70">70</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref>].</p><p>The prohormones of ANP, ADM and ET-1 are released in equimolar ratios to the vasoactive hormones but have a longer half-life. The mid-regional (MR) fragments of proANP and proADM are also more stable <italic>in vivo</italic> and <italic>ex vivo</italic> than the amino- or carboxy-terminal part of the prohormone, thereby minimizing the risk of underestimation of levels as a result of early degradation of crucial epitopes at the extreme ends of the molecule [<xref ref-type="bibr" rid="CR73">73</xref>]. In studies of patients with established heart failure, elevated levels of MR-proANP, MR-proADM and carboxy-terminal fragment of ET-1 (CT-proET-1) have been shown to be associated with mortality independently of clinical variables, and the biomarkers have displayed prognostic and discriminatory value that has compared favorably with BNP and/or NT-proBNP in the heart failure population [<xref ref-type="bibr" rid="CR70">70</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref>].</p><sec id="Sec5"><title>Secretory Phospholipase A2</title><p>Secretory phospholipase A2 (sPLA2) and lipoprotein-associated phospholipase A2 (Lp-PLA2) are enzyme biomarkers of increased cardiovascular risk [<xref ref-type="bibr" rid="CR74">74</xref>]. In addition, arachidonic acid release from membrane phospholipids by PLA2 is a key step in the control of eicosanoid. sPLA2 and Lp-PLA2 appear to be prospective candidates for inhibition [<xref ref-type="bibr" rid="CR75">75</xref>]. High-dose atorvastatin significantly reduces sPLA2 and Lp-PLA2 mass and activity after acute coronary syndromes and mitigates the risk of death associated with sPLA2 mass. Atorvastatin may exert anti-inflammatory effects on phospholipases that contribute to its therapeutic benefit after acute coronary syndromes [<xref ref-type="bibr" rid="CR74">74</xref>].</p></sec><sec id="Sec6"><title>Lp-PLA2</title><p>Lp-PLA2 is a vascular specific marker that is not elevated in other inflammatory processes [<xref ref-type="bibr" rid="CR76">76</xref>]. Lp-PLA2 is produced in atherosclerotic plaque by macrophages, T cells and mast cells, is highly concentrated in rupture prone lesions, and is bound to low-density and high-density lipoprotein (LDL and HDL) [<xref ref-type="bibr" rid="CR77">77</xref>]. Statins have been shown to decrease Lp-PLA2 but not to the same extent as their effect on LDL levels, suggesting the potential for therapies that can more specifically target Lp-PLA2.</p></sec><sec id="Sec7"><title>sPLA2</title><p>Type IIA sPLA2 is expressed in hepatocytes, macrophages, platelets and vascular smooth muscle cells, and its plasma levels are upregulated by proinflammatory compounds such as interleukin-1, interleukin-6, tumor necrosis factor, interferon and oxidized LDL. sPLA2 can also hydrolyze unmodified phospholipids, in contrast to Lp-PLA2 [<xref ref-type="bibr" rid="CR78">78</xref>]. It has been shown that human atherosclerotic lesions contain extracellular and intracellular sPLA2 (macrophages and smooth muscle cells) [<xref ref-type="bibr" rid="CR79">79</xref>]. sPLA2 is less vascular specific than Lp-PLA2. sPLA2 correlates with high sensitivity C Reactive Protein (hs-CRP) levels and is an acute-phase reactant [<xref ref-type="bibr" rid="CR76">76</xref>]. Elevated sPLA2 levels predict coronary heart disease in patients with stable and unstable angina and normal subjects [<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>].</p></sec><sec id="Sec8"><title>Assays</title><p>sPLA2 and Lp-PLA2 can be measured as mass or activity. There is some dispute over the best measurement to use. Most studies have used mass. There are a number of competing Lp-PLA2 mass assays on the market and different assays have been utilized in different studies with varying results reported. The United States Food and Drug Administration approved a blood test to measure Lp-PLA2 mass as a marker of cardiovascular disease (CVD) risk in 2005 (PLAC diaDexus, California, United States). Correlation between Lp-PLA2 mass and activity is variable depending on the clinical scenario as Lp-PLA2 levels are dependent on circulating LDL and HDL levels.</p></sec><sec id="Sec9"><title>Coronary plaque burden</title><p>Underlying coronary disease is a prerequisite for acute coronary syndromes. Coronary artery calcification is a direct sign of atherosclerotic CAD [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>] and has been shown to be a strong predictor for risk of cardiovascular disease or events, including myocardial infarction and/or cardiac death [<xref ref-type="bibr" rid="CR87">87</xref>&#x02013;<xref ref-type="bibr" rid="CR89">89</xref>]. The amount of coronary calcium can be quantified non-invasively by using computed tomography (CT) techniques and calculating the volume score [<xref ref-type="bibr" rid="CR90">90</xref>]. The majority of perioperative troponin elevations occur in patients with underlying CAD [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Conceivably, patients with a higher burden of CAD would derive the most benefit from interventions aimed at reducing PMI.</p></sec></sec></sec><sec id="Sec10"><title>Methods/Design</title><p>This is a prospective, single-centre (Northern Hospital, Victoria, Australia), open-label, 2x2 factorial, randomized controlled trial of ivabradine and atorvastatin in the prevention of myocardial injury following emergent orthopedic surgery for lower limb fracture. The Northern Hospital Ethics Committee approved this study on 6 July 2012 (reference number HREC P06/12). This study complies with the Declaration of Helsinki. Informed consent will be obtained from all participating patients. Upon signing informed consent, the patient&#x02019;s data will be populated as per protocol.</p><sec id="Sec11"><title>Primary outcome measure</title><p>Based on the peak troponin I level postoperative day 1, 2, 3 and 4, the primary outcome measure will be the frequency (binary outcome) and magnitude (continuous variable) of new myocardial injury following emergent orthopedic surgery for lower limb fracture. A troponin I level of less than 0.04&#x000a0;&#x003bc;g/L is considered positive in our reference laboratory.</p></sec><sec id="Sec12"><title>Secondary outcome measures</title><p>The secondary outcome measures will be as follows: myocardial infarction according to the universal definition [<xref ref-type="bibr" rid="CR8">8</xref>]; death in-hospital, at 30&#x000a0;days and 12&#x000a0;months; stroke in-hospital, at 30&#x000a0;days and 12&#x000a0;months; markers of myocardial stress: NT-proBNP (pmol/L), MR-proANP (pmol/L), MR-proADM (nmol/L) and CT-proET-1 (pmol/L); and markers of plaque burden: sPLA2 and Lp-PLA2 mass (%) and activity (%). There are also several outcomes that will be monitored for safety purposes: symptomatic bradycardia or heart block requiring the cessation of ivabradine, and liver enzyme elevation more than three times the upper limits of normal (ALP, GGT, AST and ALT measured in U/L) requiring the cessation of atorvastatin.</p></sec><sec id="Sec13"><title>Study population</title><p>The study aims to recruit 200 patients over the age of 60&#x000a0;years admitted to Northern Hospital with fractured neck of femur who are planned to undergo surgery within 48&#x000a0;hours.</p></sec><sec id="Sec14"><title>Inclusion criteria</title><p>Patients may be included in the trial if they are over 60&#x000a0;years of age and have a NOF fracture with surgical treatment planned for within the next 48&#x000a0;hours.</p></sec><sec id="Sec15"><title>Exclusion criteria</title><p>Patients who meet any of the following criteria will be excluded from the study: 1) current ivabradine use, current atorvastatin use of 80&#x000a0;mg daily, 3) heart rate &#x0003c;65&#x000a0;bpm prior to randomization, 4) known liver disease or liver enzymes more than three times the higher limit of normal, 5) preoperative troponin elevation, 6) artificial pacemakers, sick sinus syndrome or complete heart block, 7) concomitant CYP3A4 inhibitors (ketoconazole, macrolides, cyclosporin, gestodene and antiretrovirals), 8) significant cognitive disorders, and 9) patients who do not undergo surgical treatment for lower limb fracture for any reason. If such patients were initially enrolled they will be excluded from the analysis (per protocol analysis).</p></sec><sec id="Sec16"><title>Randomization protocol</title><p>Patients will be randomized using a computerized block randomization method with blocks of variable sizes to ensure &#x02018;true&#x02019; randomization and equal numbers in each treatment group. Patients will be randomized to one of four groups in a 1:1:1:1 ratio: no treatment (control group), atorvastatin 80&#x000a0;mg daily, ivabradine twice daily (as per protocol), or ivabradine twice daily (as per protocol) and atorvastatin 80&#x000a0;mg daily.</p></sec><sec id="Sec17"><title>Ivabradine protocol</title><p>Open-label ivabradine will be administered according to the following protocol.</p><p>Heart rate 65 to 90&#x000a0;bpm at randomization: starting dose of 5.0&#x000a0;mg administered orally twice daily commencing immediately after randomization (within two hours and prior to surgery) and continued until discharge. Heart rate &#x0003e;90&#x000a0;bpm at randomization: starting dose of 7.5&#x000a0;mg administered orally twice daily commencing immediately after randomization (within two hours and prior to surgery) and continued until discharge. ivabradine dose and heart rate will be reviewed on a daily basis by the cardiology research fellow (associate investigator) and adjusted as follows: 1) if heart rate remains over 65&#x000a0;bpm during treatment then ivabradine dosage will be increased by 2.5&#x000a0;mg twice daily to a maximum of 7.5&#x000a0;mg twice daily; 2) if heart rate falls below 50&#x000a0;bpm during treatment then ivabradine dosage will be reduced by 2.5&#x000a0;mg twice daily; and finally 3) if heart rate remains below 50&#x000a0;bpm on ivabradine 2.5&#x000a0;mg twice daily then ivabradine will be ceased.</p></sec><sec id="Sec18"><title>Atorvastatin protocol</title><p>Open-label atorvastatin will be administered according to the following protocol. A dosage of 80&#x000a0;mg administered orally daily will commence immediately after randomization (within two hours and prior to surgery) and will continue until discharge (unless otherwise indicated according to history and lipid profile). A liver function test and creatinine kinase levels will be monitored to assess side effects.</p></sec><sec id="Sec19"><title>Electrocardiography protocol</title><p>A digital 12-lead ECG will be recorded preoperatively and on postoperative days 1, 2 and 3 and assessed for heart rate, PR interval, QRS duration and morphology, Q waves, QT duration and QTc, as well as ST-T morphology and overall interpretation to look for changes that meet the universal definition of myocardial infarction.</p></sec><sec id="Sec20"><title>Echocardiography protocol</title><p>A transthoracic echocardiogram will be done on every patient prior to discharge to assess for evidence of regional wall motion abnormality, systolic and diastolic dysfunction. Images of the left ventricle in motion and hemodynamic measures will be recorded at rest.</p></sec><sec id="Sec21"><title>Holter protocol</title><p>Continuous 48-hour Holter monitoring will be commenced within 24&#x000a0;hour postoperatively to assess for heart rate, postoperative arrhythmia including atrial fibrillation, its frequency and its duration.</p></sec><sec id="Sec22"><title>CT coronary calcium protocol</title><p>A non-invasive, non-contrast CT coronary calcium score will be acquired on a 320-detector row CT scanner (Toshiba Aquilion ONE, Toshiba Medical Systems, Otawara, Japan) prior to or at discharge following surgery. The scan range will be planned between the carina and cardiac apex. Depending on the expected scan range, a 320&#x02009;&#x000d7;&#x02009;0.5&#x000a0;mm or a 280&#x02009;&#x000d7;&#x02009;0.5&#x000a0;mm detector configuration will be used as previously described [<xref ref-type="bibr" rid="CR91">91</xref>]. Immediately before image acquisition, an optimal reconstruction phase will be automatically determined during a breath hold exercise with ECG-recording by use of cardiac scanning software (SureCardio, Toshiba Medical Systems, Otawara, Japan). Full cardiac calcium score acquisition will be performed in a single gantry rotation (0.35&#x000a0;seconds) during breath hold at inspiration that allows image reconstruction at a single cardiac phase. Scan parameters: tube voltage 120&#x000a0;kV and tube current 200 to 400&#x000a0;mA (dependent on patient size and shape as visually assessed by the radiology technician: 200&#x000a0;mA for small and/or thin patients, 250&#x000a0;mA for normal patients and 300 to 400&#x000a0;mA for large and/or obese patients).</p><p>Image reconstruction will be performed using a standard reconstruction kernel filter from the cardiac scanning software (SureCardio, Toshiba Medical Systems, Otawara, Japan) with a 200 to 220&#x000a0;mm<sup>2</sup> field of view. Non-overlapping 0.5&#x000a0;mm datasets will be reconstructed for evaluation of coronary calcium, and the reconstructions transferred to a post-processing workstation for analysis.</p><p>Calcium volume scores (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) will be performed on a post-processing workstation (Vitrea FX, version 1.0, Vital Images, Minnetonka, United States), using calcium score analysis software (VScore, Vital Images). Coronary calcium will be defined as an area of at least three &#x02018;face-connected&#x02019; voxels in the axial plane in the course of a coronary artery, with an attenuation threshold-value of &#x02265;130 Hounsfield units (HU).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Calcium score interpretation</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3">Translation of calcium score</th></tr><tr><th>Calcium score</th><th>Implication</th><th>Risk of coronary artery disease</th></tr></thead><tbody><tr><td>0</td><td>No identifiable plaque</td><td>Very low, generally less than 5%</td></tr><tr><td>1 &#x02013; 10</td><td>Minimal identifiable plaque</td><td>Very unlikely, less than 10%</td></tr><tr><td>11 &#x02013; 100</td><td>Definite, at least mild atherosclerotic plaque</td><td>Mild or minimal coronary narrowings likely</td></tr><tr><td>101 &#x02013; 400</td><td>Definite, at least moderate atherosclerotic plaque</td><td>Mild coronary artery disease highly likely, significant narrowings possible</td></tr><tr><td>401 or higher</td><td>Extensive atherosclerotic plaque</td><td>High likelihood of at least one significant coronary narrowing</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec23"><title>Troponin I</title><p>Serum for troponin I measurement will be taken preoperatively (within two hours of randomization) and on days 1, 2, 3 and 4 postoperatively. Serum will be stored at -70&#x000b0;C. Prior to analysis, the frozen serum will be thawed, thoroughly mixed and re-centrifuged.</p><p>Troponin I will be measured using the Architect STAT Troponin I assay (Abbott Diagnostics, Abbot Park, IL, USA). The 99th percentile of a healthy reference population using this assay has been previously established at 0.03 mcg/l and levels above this are considered indicative of myocardial injury. The coefficient of variation (CV) for this assay is 10% at the 99th percentile.</p></sec><sec id="Sec24"><title>Markers of cardiovascular stress</title><p>Levels of MR-proANP, MR-proADM and CT-proET-1 will be determined using the Time-Resolved-Amplified-Cryptate-Emission (TRACE) technology on the Kryptor Compact analyzers (BRAHMS GmbH, Henningsdorf, Germany), from samples collected at the same time points as troponin.</p><p>T-pro-BNP levels will be measured using the Elecsys electrochemiluminescence immunoassay (ECLIA) proBNP II assay on a Roche Cobas E170 analyzer (Roche, Indianapolis, IN), from samples collected at the same time points as troponin. This assay uses two polyclonal antibodies that recognize epitopes located on the N-terminal part of pro-BNP. The lower limit of the detection range (sensitivity) is 5&#x000a0;pg/ml. Within-run coefficients of variation are 1.9% at a concentration of 64&#x000a0;pg/ml and 1.3% at 14,142&#x000a0;pg/ml. Total precision coefficients of variation are 3.1% at a concentration of 36&#x000a0;pg/ml and 2.7% at 125&#x000a0;pg/ml. Levels of the biomarkers of the renin-angiotensin pathway, including Ace2, will be measured.</p></sec><sec id="Sec25"><title>Markers of plaque burden</title><p>Total cholesterol, triglycerides, HDL and LDL will be measured at randomization (fasting sample just prior to surgery) and again on day 2 postoperatively (fasting sample), using the same venipuncture as the preoperative and day 2 troponin measurement.</p><p>sPLA2 and Lp-PLA2 mass and activity assays will be performed at the same time point as fasting lipids. Lp-PLA2 and sPLA2 mass will be measured with an ELISA based assay (sPLA2: Cayman Chemical Co., Ann Arbor, Michigan, United States and Lp-PLA2: diaDexus Co. California, United States). sPLA2 activity is measured by a fluorometric assay. All blood samples will be collected and put on ice prior to centrifugation, separation and storage at &#x02013;80&#x000b0;C in a dedicated secure freezer. Batch testing will then be performed at a later date.</p></sec><sec id="Sec26"><title>Follow-up protocol</title><p>All patients will be followed up on by means of a semi-structured interview (via telephone call) at 30&#x000a0;days, 6&#x000a0;months and 1&#x000a0;year, enquiring about any cardiac events, hospitalizations, functional level and medication usage. Additionally their medical records will be retrieved and/or primary physician contacted for more information. Deaths will be confirmed with the Births, Marriages and Deaths registry.</p></sec><sec id="Sec27"><title>Sample size calculation</title><p>We estimated that 200 patients (calculated sample size of 171) would be required to have a power of 0.90 (alpha&#x02009;=&#x02009;0.05, two tail) to identify a difference(moderate effect size (f&#x02009;=&#x02009;0.25) in PMI incidence between the 4 groups. (F test Anova:fixed effects,special,main effects and interactions; Analysis: a priori).</p><p>We plan to recruit 200 patients in total (50 in each treatment cell), providing an actual power of 0.94 to detect a moderate effect size.</p></sec><sec id="Sec28"><title>Statistical analysis</title><p>A comprehensive statistical analysis will be performed using SPSS (IBM, USA) for the <italic>a priori</italic> hypotheses. Baseline characteristics will be reported as mean&#x02009;&#x000b1;&#x02009;SD for normally distributed continuous variables, and as counts (percentages) for categorical variables. The Spearman correlation will be used to calculate the association between different biomarkers. A Cox proportional-hazards model will be used to examine the association between biomarker levels and outcomes. A value of <italic>P</italic> &#x0003c;0.05 will be considered statistically significant.</p></sec></sec><sec id="Sec29" sec-type="discussion"><title>Discussion</title><p>Through this study, we postulate that ivabradine will reduce the rate and magnitude of PMI following emergent lower limb orthopedic surgery by reducing heart rate and attenuating catecholamine-induced tachycardia postoperatively. Secondly, we postulate that postoperative reduction in heart rate and catecholamine-induced tachycardia with ivabradine will correlate with a reduction in biomarkers of cardiovascular stress as measured by NT-proBNP, MR-proANP, MR-proADM and CT-proET-1, which will reduce atrial stretch and postoperative incidence of atrial fibrillation. We further postulate that atorvastatin will reduce the rate and magnitude of PMI following emergent lower limb orthopedic surgery via a reduction in sPLA2 and Lp-PLA2 mass.</p><p>To conclude, we aim to demonstrate that treatment with ivabradine and atorvastatin will cause a reduction in the incidence and magnitude of PMI, the benefit of which is derived primarily in patients with greater atherosclerotic burden as measured by higher CT coronary calcium scores.</p></sec><sec id="Sec30"><title>Trial status</title><p>This study is currently recruiting participants since 2012 and finishes once 200 patients are recruited.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>Ace2</term><def><p>Angiotensin-converting enzyme 2</p></def></def-item><def-item><term>ADM</term><def><p>Adrenomedullin</p></def></def-item><def-item><term>ADP</term><def><p>Adenosine diphosphate</p></def></def-item><def-item><term>AF</term><def><p>Atrial fibrillation</p></def></def-item><def-item><term>ANP</term><def><p>Atrial natriuretic peptide</p></def></def-item><def-item><term>BNP</term><def><p>B-type natriuretic peptide</p></def></def-item><def-item><term>CAD</term><def><p>Coronary artery disease</p></def></def-item><def-item><term>CT</term><def><p>Computed tomography</p></def></def-item><def-item><term>CT-proET-1</term><def><p>Carboxy terminal fragment of ET-1</p></def></def-item><def-item><term>ECG</term><def><p>Electrocardiogram</p></def></def-item><def-item><term>ECLIA</term><def><p>Elecysys electrochemiluminescence immunoassay</p></def></def-item><def-item><term>ENOS</term><def><p>Endothelial nitric oxide synthase</p></def></def-item><def-item><term>ET-1</term><def><p>Endothelin-1</p></def></def-item><def-item><term>HDL</term><def><p>High-density lipoprotein</p></def></def-item><def-item><term>hs-CRP</term><def><p>High sensitivity C-reactive protein</p></def></def-item><def-item><term>HU</term><def><p>Hounsfield units</p></def></def-item><def-item><term>LDL</term><def><p>Low-density lipoprotein</p></def></def-item><def-item><term>Lp-PLA2</term><def><p>Lipoprotein-associated phospholipase A2</p></def></def-item><def-item><term>MR</term><def><p>Mid-regional fragments</p></def></def-item><def-item><term>NOF</term><def><p>Neck of femur</p></def></def-item><def-item><term>NT-proBNP</term><def><p>Aminoterminal fragment of prohormone B-type natriuretic peptide</p></def></def-item><def-item><term>PCI</term><def><p>Percutaneous coronary intervention</p></def></def-item><def-item><term>PMI</term><def><p>Perioperative myocardial infarction</p></def></def-item><def-item><term>sPLA2</term><def><p>Secretory phospholipase A2</p></def></def-item><def-item><term>TRACE</term><def><p>Time-resolved amplified cryptate emission.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>VM, IS, NR and MAU collaborated on the work in literature review and writing the protocol. VM and IS liaised to obtained ethics approval. NR and MAU were also involved in the preparation of laboratory technical references. WVG as the Head of Department has been guiding in methods preparation, especially in statistics. Additionally, IS is actively listed as main correspondence on this protocol submission. All authors read and approved the final manuscript.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>MJ</given-names></name><name><surname>Owings</surname><given-names>MF</given-names></name></person-group><article-title>2000 National Hospital Discharge Survey: Advance Data From Vital and Health Statistics, No. 329. Hyattsville, Md</article-title><source>National Center for Health Statistics</source><year>2002</year></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>DT</given-names></name></person-group><article-title>Perioperative cardiac morbidity</article-title><source>Anesthesiology</source><year>1990</year><volume>72</volume><fpage>153</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1097/00000542-199001000-00025</pub-id><pub-id pub-id-type="pmid">2404426</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiser</surname><given-names>TG</given-names></name><name><surname>Regenbogen</surname><given-names>SE</given-names></name><name><surname>Thompson</surname><given-names>KD</given-names></name><name><surname>Haynes</surname><given-names>AB</given-names></name><name><surname>Lipsitz</surname><given-names>SR</given-names></name><name><surname>Berry</surname><given-names>WR</given-names></name><name><surname>Gawande</surname><given-names>AA</given-names></name></person-group><article-title>An estimation of the global volume of surgery: a modelling strategy based on available data</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60878-8</pub-id><pub-id pub-id-type="pmid">18582931</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Marcantonio</surname><given-names>ER</given-names></name><name><surname>Mangione</surname><given-names>CM</given-names></name><name><surname>Thomas</surname><given-names>EJ</given-names></name><name><surname>Polanczyk</surname><given-names>CA</given-names></name><name><surname>Cook</surname><given-names>EF</given-names></name><name><surname>Sugarbaker</surname><given-names>DJ</given-names></name><name><surname>Donaldson</surname><given-names>MC</given-names></name><name><surname>Poss</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>KK</given-names></name><name><surname>Ludwig</surname><given-names>LE</given-names></name><name><surname>Pedan</surname><given-names>A</given-names></name><name><surname>Goldman</surname><given-names>L</given-names></name></person-group><article-title>Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>1043</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.100.10.1043</pub-id><pub-id pub-id-type="pmid">10477528</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poldermans</surname><given-names>D</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Thomson</surname><given-names>IR</given-names></name><name><surname>van de Ven</surname><given-names>LL</given-names></name><name><surname>Blankensteijn</surname><given-names>JD</given-names></name><name><surname>Baars</surname><given-names>HF</given-names></name><name><surname>Yo</surname><given-names>TI</given-names></name><name><surname>Trocino</surname><given-names>G</given-names></name><name><surname>Vigna</surname><given-names>C</given-names></name><name><surname>Roelandt</surname><given-names>JR</given-names></name><name><surname>van Urk</surname><given-names>H</given-names></name></person-group><article-title>The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1789</fpage><lpage>1794</lpage><pub-id pub-id-type="doi">10.1056/NEJM199912093412402</pub-id><pub-id pub-id-type="pmid">10588963</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindenauer</surname><given-names>PK</given-names></name><name><surname>Fitzgerald</surname><given-names>J</given-names></name><name><surname>Hoople</surname><given-names>N</given-names></name><name><surname>Benjamin</surname><given-names>EM</given-names></name></person-group><article-title>The potential preventability of postoperative myocardial infarction: underuse of perioperative beta-adrenergic blockade</article-title><source>Arch Intern Med</source><year>2004</year><volume>164</volume><fpage>762</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1001/archinte.164.7.762</pub-id><pub-id pub-id-type="pmid">15078646</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nettleman</surname><given-names>MD</given-names></name><name><surname>Banitt</surname><given-names>L</given-names></name><name><surname>Barry</surname><given-names>W</given-names></name><name><surname>Awan</surname><given-names>I</given-names></name><name><surname>Gordon</surname><given-names>EE</given-names></name></person-group><article-title>Predictors of survival and the role of gender in postoperative myocardial infarction</article-title><source>Am J Med</source><year>1997</year><volume>103</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(97)00162-9</pub-id><pub-id pub-id-type="pmid">9375702</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>White</surname><given-names>HD</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><name><surname>Apple</surname><given-names>FS</given-names></name><name><surname>Galvani</surname><given-names>M</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name><name><surname>Newby</surname><given-names>LK</given-names></name><name><surname>Ravkilde</surname><given-names>J</given-names></name><name><surname>Chaitman</surname><given-names>B</given-names></name><name><surname>Clemmensen</surname><given-names>PM</given-names></name><name><surname>Dellborg</surname><given-names>M</given-names></name><name><surname>Hod</surname><given-names>H</given-names></name><name><surname>Porela</surname><given-names>P</given-names></name><name><surname>Underwood</surname><given-names>R</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Beller</surname><given-names>GA</given-names></name><name><surname>Bonow</surname><given-names>R</given-names></name><name><surname>Van der Wall</surname><given-names>EE</given-names></name><name><surname>Bassand</surname><given-names>JP</given-names></name><name><surname>Wijns</surname><given-names>W</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Uretsky</surname><given-names>BF</given-names></name><name><surname>Williams</surname><given-names>DO</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>2634</fpage><lpage>2653</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.187397</pub-id><pub-id pub-id-type="pmid">17951284</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>CP</given-names></name><name><surname>van Gaal</surname><given-names>WJ</given-names></name><name><surname>Savige</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>WK</given-names></name></person-group><article-title>Cardiac injury and troponin testing after orthopaedic surgery</article-title><source>Injury</source><year>2011</year><volume>42</volume><fpage>855</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2009.10.015</pub-id><pub-id pub-id-type="pmid">22081813</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bursi</surname><given-names>F</given-names></name><name><surname>Babuin</surname><given-names>L</given-names></name><name><surname>Barbieri</surname><given-names>A</given-names></name><name><surname>Politi</surname><given-names>L</given-names></name><name><surname>Zennaro</surname><given-names>M</given-names></name><name><surname>Grimaldi</surname><given-names>T</given-names></name><name><surname>Rumolo</surname><given-names>A</given-names></name><name><surname>Gargiulo</surname><given-names>M</given-names></name><name><surname>Stella</surname><given-names>A</given-names></name><name><surname>Modena</surname><given-names>MG</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name></person-group><article-title>Vascular surgery patients: perioperative and long-term risk according to the ACC/AHA guidelines, the additive role of post-operative troponin elevation</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><fpage>2448</fpage><lpage>2456</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehi430</pub-id><pub-id pub-id-type="pmid">16055493</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landesberg</surname><given-names>G</given-names></name><name><surname>Shatz</surname><given-names>V</given-names></name><name><surname>Akopnik</surname><given-names>I</given-names></name><name><surname>Wolf</surname><given-names>YG</given-names></name><name><surname>Mayer</surname><given-names>M</given-names></name><name><surname>Berlatzky</surname><given-names>Y</given-names></name><name><surname>Weissman</surname><given-names>C</given-names></name><name><surname>Mosseri</surname><given-names>M</given-names></name></person-group><article-title>Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>42</volume><fpage>1547</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2003.05.001</pub-id><pub-id pub-id-type="pmid">14607436</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porto</surname><given-names>I</given-names></name><name><surname>Selvanayagam</surname><given-names>JB</given-names></name><name><surname>van Gaal</surname><given-names>WJ</given-names></name><name><surname>Prati</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Channon</surname><given-names>K</given-names></name><name><surname>Neubauer</surname><given-names>S</given-names></name><name><surname>Banning</surname><given-names>AP</given-names></name></person-group><article-title>Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>662</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.593210</pub-id><pub-id pub-id-type="pmid">16894040</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>CP</given-names></name><name><surname>Lam</surname><given-names>QT</given-names></name><name><surname>Ryan</surname><given-names>JE</given-names></name><name><surname>Sinnappu</surname><given-names>RN</given-names></name><name><surname>Lim</surname><given-names>WK</given-names></name></person-group><article-title>Incidence of post-operative troponin I rises and 1-year mortality after emergency orthopaedic surgery in older patients</article-title><source>Age Ageing</source><year>2009</year><volume>38</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1093/ageing/afn231</pub-id><pub-id pub-id-type="pmid">19008306</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>CP</given-names></name><name><surname>van Gaal</surname><given-names>WJ</given-names></name><name><surname>Ryan</surname><given-names>JE</given-names></name><name><surname>Profitis</surname><given-names>K</given-names></name><name><surname>Savige</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>WK</given-names></name></person-group><article-title>Does cardiology intervention improve mortality for post-operative troponin elevations after emergency orthopaedic-geriatric surgery? A randomised controlled study</article-title><source>Injury</source><year>2012</year><volume>43</volume><fpage>1193</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2012.03.034</pub-id><pub-id pub-id-type="pmid">22541758</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landesberg</surname><given-names>G</given-names></name><name><surname>Beattie</surname><given-names>WS</given-names></name><name><surname>Mosseri</surname><given-names>M</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name></person-group><article-title>Perioperative myocardial infarction</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>2936</fpage><lpage>2944</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.828228</pub-id><pub-id pub-id-type="pmid">19506125</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landesberg</surname><given-names>G</given-names></name><name><surname>Mosseri</surname><given-names>M</given-names></name><name><surname>Zahger</surname><given-names>D</given-names></name><name><surname>Wolf</surname><given-names>Y</given-names></name><name><surname>Perouansky</surname><given-names>M</given-names></name><name><surname>Anner</surname><given-names>H</given-names></name><name><surname>Drenger</surname><given-names>B</given-names></name><name><surname>Hasin</surname><given-names>Y</given-names></name><name><surname>Berlatzky</surname><given-names>Y</given-names></name><name><surname>Weissman</surname><given-names>C</given-names></name></person-group><article-title>Myocardial infarction after vascular surgery: the role of prolonged stress-induced, ST depression-type ischemia</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><fpage>1839</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01265-7</pub-id><pub-id pub-id-type="pmid">11401120</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feringa</surname><given-names>HH</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Kertai</surname><given-names>MD</given-names></name><name><surname>Meij</surname><given-names>SH</given-names></name><name><surname>Galal</surname><given-names>W</given-names></name><name><surname>Schouten</surname><given-names>O</given-names></name><name><surname>Thomson</surname><given-names>IR</given-names></name><name><surname>Klootwijk</surname><given-names>P</given-names></name><name><surname>van Sambeek</surname><given-names>MR</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Poldermans</surname><given-names>D</given-names></name></person-group><article-title>High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>I344</fpage><lpage>I349</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.000463</pub-id><pub-id pub-id-type="pmid">16820598</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukumoto</surname><given-names>Y</given-names></name><name><surname>Hiro</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>G</given-names></name><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>J</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Matsuzaki</surname><given-names>M</given-names></name></person-group><article-title>Localized elevation of shear stress is related to coronary plaque rupture: a 3-dimensional intravascular ultrasound study with in-vivo color mapping of shear stress distribution</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><fpage>645</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.10.030</pub-id><pub-id pub-id-type="pmid">18261684</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>DT</given-names></name><name><surname>Browner</surname><given-names>WS</given-names></name><name><surname>Hollenberg</surname><given-names>M</given-names></name><name><surname>London</surname><given-names>MJ</given-names></name><name><surname>Tubau</surname><given-names>JF</given-names></name><name><surname>Tateo</surname><given-names>IM</given-names></name></person-group><article-title>Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group</article-title><source>N Engl J Med</source><year>1990</year><volume>323</volume><fpage>1781</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1056/NEJM199012273232601</pub-id><pub-id pub-id-type="pmid">2247116</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browner</surname><given-names>WS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Mangano</surname><given-names>DT</given-names></name></person-group><article-title>In-hospital and long-term mortality in male veterans following noncardiac surgery. The Study of Perioperative Ischemia Research Group</article-title><source>JAMA</source><year>1992</year><volume>268</volume><fpage>228</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1001/jama.1992.03490020076034</pub-id><pub-id pub-id-type="pmid">1608142</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>SM</given-names></name><name><surname>Beattie</surname><given-names>C</given-names></name><name><surname>Christopherson</surname><given-names>R</given-names></name><name><surname>Rock</surname><given-names>P</given-names></name><name><surname>Parker</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>SO</given-names></name></person-group><article-title>Perioperative rate-related silent myocardial ischemia and postoperative death</article-title><source>J Clin Anesth</source><year>1990</year><volume>2</volume><fpage>326</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/0952-8180(90)90079-I</pub-id><pub-id pub-id-type="pmid">2271196</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleisher</surname><given-names>LA</given-names></name><name><surname>Nelson</surname><given-names>AH</given-names></name><name><surname>Rosenbaum</surname><given-names>SH</given-names></name></person-group><article-title>Postoperative myocardial ischemia: etiology of cardiac morbidity or manifestation of underlying disease?</article-title><source>J Clin Anesth</source><year>1995</year><volume>7</volume><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/0952-8180(94)00030-8</pub-id><pub-id pub-id-type="pmid">7598933</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landesberg</surname><given-names>G</given-names></name><name><surname>Luria</surname><given-names>MH</given-names></name><name><surname>Cotev</surname><given-names>S</given-names></name><name><surname>Eidelman</surname><given-names>LA</given-names></name><name><surname>Anner</surname><given-names>H</given-names></name><name><surname>Mosseri</surname><given-names>M</given-names></name><name><surname>Schechter</surname><given-names>D</given-names></name><name><surname>Assaf</surname><given-names>J</given-names></name><name><surname>Erel</surname><given-names>J</given-names></name><name><surname>Berlatzky</surname><given-names>Y</given-names></name></person-group><article-title>Importance of long-duration postoperative ST-segment depression in cardiac morbidity after vascular surgery</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>715</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)90486-Z</pub-id><pub-id pub-id-type="pmid">8095624</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>DT</given-names></name><name><surname>Hollenberg</surname><given-names>M</given-names></name><name><surname>Fegert</surname><given-names>G</given-names></name><name><surname>Meyer</surname><given-names>ML</given-names></name><name><surname>London</surname><given-names>MJ</given-names></name><name><surname>Tubau</surname><given-names>JF</given-names></name><name><surname>Krupski</surname><given-names>WC</given-names></name></person-group><article-title>Perioperative myocardial ischemia in patients undergoing noncardiac surgery&#x02013;I: Incidence and severity during the 4&#x000a0;day perioperative period. The Study of Perioperative Ischemia (SPI) Research Group</article-title><source>J Am Coll Cardiol</source><year>1991</year><volume>17</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(91)90863-5</pub-id><pub-id pub-id-type="pmid">1999618</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>HJ</given-names></name><name><surname>Rabethge</surname><given-names>S</given-names></name><name><surname>Luiz</surname><given-names>T</given-names></name><name><surname>Haux</surname><given-names>P</given-names></name></person-group><article-title>Perioperative ST-segment depression and troponin T release. Identification of patients with highest risk for myocardial damage</article-title><source>Acta Anaesthesiol Scand</source><year>1999</year><volume>43</volume><fpage>124</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1034/j.1399-6576.1999.430202.x</pub-id><pub-id pub-id-type="pmid">10027017</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>DT</given-names></name><name><surname>Layug</surname><given-names>EL</given-names></name><name><surname>Wallace</surname><given-names>A</given-names></name><name><surname>Tateo</surname><given-names>I</given-names></name></person-group><article-title>Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>1713</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJM199612053352301</pub-id><pub-id pub-id-type="pmid">8929262</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Raymer</surname><given-names>K</given-names></name><name><surname>Butler</surname><given-names>R</given-names></name><name><surname>Parlow</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name></person-group><article-title>The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial</article-title><source>Am Heart J</source><year>2006</year><volume>152</volume><fpage>983</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2006.07.024</pub-id><pub-id pub-id-type="pmid">17070177</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juul</surname><given-names>AB</given-names></name><name><surname>Wetterslev</surname><given-names>J</given-names></name><name><surname>Gluud</surname><given-names>C</given-names></name><name><surname>Kofoed-Enevoldsen</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>G</given-names></name><name><surname>Callesen</surname><given-names>T</given-names></name><name><surname>Norgaard</surname><given-names>P</given-names></name><name><surname>Fruergaard</surname><given-names>K</given-names></name><name><surname>Bestle</surname><given-names>M</given-names></name><name><surname>Vedelsdal</surname><given-names>R</given-names></name><name><surname>Miran</surname><given-names>A</given-names></name><name><surname>Jacobsen</surname><given-names>J</given-names></name><name><surname>Roed</surname><given-names>J</given-names></name><name><surname>Mortensen</surname><given-names>MB</given-names></name><name><surname>Jorgensen</surname><given-names>L</given-names></name><name><surname>Jorgensen</surname><given-names>J</given-names></name><name><surname>Rovsing</surname><given-names>ML</given-names></name><name><surname>Petersen</surname><given-names>PL</given-names></name><name><surname>Pott</surname><given-names>F</given-names></name><name><surname>Haas</surname><given-names>M</given-names></name><name><surname>Albret</surname><given-names>R</given-names></name><name><surname>Nielsen</surname><given-names>LL</given-names></name><name><surname>Johansson</surname><given-names>G</given-names></name><name><surname>Stjernholm</surname><given-names>P</given-names></name><name><surname>Molgaard</surname><given-names>Y</given-names></name><name><surname>Foss</surname><given-names>NB</given-names></name><name><surname>Elkjaer</surname><given-names>J</given-names></name><name><surname>Dehlie</surname><given-names>B</given-names></name><name><surname>Boysen</surname><given-names>K</given-names></name><name><surname>Zaric</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial</article-title><source>BMJ</source><year>2006</year><volume>332</volume><fpage>1482</fpage><pub-id pub-id-type="doi">10.1136/bmj.332.7556.1482</pub-id><pub-id pub-id-type="pmid">16793810</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Beattie</surname><given-names>WS</given-names></name><name><surname>Choi</surname><given-names>PT</given-names></name><name><surname>Badner</surname><given-names>NH</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Villar</surname><given-names>JC</given-names></name><name><surname>Cina</surname><given-names>CS</given-names></name><name><surname>Leslie</surname><given-names>K</given-names></name><name><surname>Jacka</surname><given-names>MJ</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Bhandari</surname><given-names>M</given-names></name><name><surname>Avezum</surname><given-names>A</given-names></name><name><surname>Cavalcanti</surname><given-names>AB</given-names></name><name><surname>Giles</surname><given-names>JW</given-names></name><name><surname>Schricker</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Jakobsen</surname><given-names>CJ</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group><article-title>How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials</article-title><source>BMJ</source><year>2005</year><volume>331</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1136/bmj.38503.623646.8F</pub-id><pub-id pub-id-type="pmid">15996966</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Leslie</surname><given-names>K</given-names></name><name><surname>Villar</surname><given-names>JC</given-names></name><name><surname>Xavier</surname><given-names>D</given-names></name><name><surname>Chrolavicius</surname><given-names>S</given-names></name><name><surname>Greenspan</surname><given-names>L</given-names></name><name><surname>Pogue</surname><given-names>J</given-names></name><name><surname>Pais</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Malaga</surname><given-names>G</given-names></name><name><surname>Avezum</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>M</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Jacka</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>P</given-names></name></person-group><article-title>Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>1839</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60601-7</pub-id><pub-id pub-id-type="pmid">18479744</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenberg</surname><given-names>SM</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name></person-group><article-title>Noncardiac surgery: postoperative arrhythmias</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>N145</fpage><lpage>N150</lpage><pub-id pub-id-type="doi">10.1097/00003246-200010001-00006</pub-id><pub-id pub-id-type="pmid">11055683</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaporciyan</surname><given-names>AA</given-names></name><name><surname>Correa</surname><given-names>AM</given-names></name><name><surname>Rice</surname><given-names>DC</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Smythe</surname><given-names>WR</given-names></name><name><surname>Swisher</surname><given-names>SG</given-names></name><name><surname>Walsh</surname><given-names>GL</given-names></name><name><surname>Putnam</surname><given-names>JB</given-names><suffix>Jr</suffix></name></person-group><article-title>Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients</article-title><source>J Thorac Cardiovasc Surg</source><year>2004</year><volume>127</volume><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2003.07.011</pub-id><pub-id pub-id-type="pmid">15001907</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>EM</given-names></name><name><surname>Packard</surname><given-names>KA</given-names></name><name><surname>Hilleman</surname><given-names>DE</given-names></name></person-group><article-title>Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers</article-title><source>Pharmacotherapy</source><year>2010</year><volume>30</volume><fpage>749, 274e</fpage><lpage>318e</lpage><pub-id pub-id-type="doi">10.1592/phco.30.7.749</pub-id><pub-id pub-id-type="pmid">20575638</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echahidi</surname><given-names>N</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name><name><surname>O'Hara</surname><given-names>G</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name></person-group><article-title>Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><fpage>793</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.10.043</pub-id><pub-id pub-id-type="pmid">18294562</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaireviciute</surname><given-names>D</given-names></name><name><surname>Aidietis</surname><given-names>A</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Atrial fibrillation following cardiac surgery: clinical features and preventative strategies</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><fpage>410</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehn609</pub-id><pub-id pub-id-type="pmid">19174427</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayson</surname><given-names>SE</given-names></name><name><surname>Greenspon</surname><given-names>AJ</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Decaro</surname><given-names>MV</given-names></name><name><surname>Sheth</surname><given-names>M</given-names></name><name><surname>Weitz</surname><given-names>HH</given-names></name><name><surname>Whellan</surname><given-names>DJ</given-names></name></person-group><article-title>The changing face of postoperative atrial fibrillation prevention: a review of current medical therapy</article-title><source>Cardiol Rev</source><year>2007</year><volume>15</volume><fpage>231</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1097/CRD.0b013e31813e62bb</pub-id><pub-id pub-id-type="pmid">17700382</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chelazzi</surname><given-names>C</given-names></name><name><surname>Villa</surname><given-names>G</given-names></name><name><surname>De Gaudio</surname><given-names>AR</given-names></name></person-group><article-title>Postoperative atrial fibrillation</article-title><source>ISRN Cardiol</source><year>2011</year><volume>2011</volume><fpage>203179</fpage><pub-id pub-id-type="doi">10.5402/2011/203179</pub-id><pub-id pub-id-type="pmid">22347631</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiFrancesco</surname><given-names>D</given-names></name><name><surname>Camm</surname><given-names>JA</given-names></name></person-group><article-title>Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease</article-title><source>Drugs</source><year>2004</year><volume>64</volume><fpage>1757</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.2165/00003495-200464160-00003</pub-id><pub-id pub-id-type="pmid">15301560</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borer</surname><given-names>JS</given-names></name><name><surname>Fox</surname><given-names>K</given-names></name><name><surname>Jaillon</surname><given-names>P</given-names></name><name><surname>Lerebours</surname><given-names>G</given-names></name></person-group><article-title>Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>817</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000048143.25023.87</pub-id><pub-id pub-id-type="pmid">12591750</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joannides</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>N</given-names></name><name><surname>Iacob</surname><given-names>M</given-names></name><name><surname>Compagnon</surname><given-names>P</given-names></name><name><surname>Lerebours</surname><given-names>G</given-names></name><name><surname>Menard</surname><given-names>JF</given-names></name><name><surname>Thuillez</surname><given-names>C</given-names></name></person-group><article-title>Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise</article-title><source>Br J Clin Pharmacol</source><year>2006</year><volume>61</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2005.02544.x</pub-id><pub-id pub-id-type="pmid">16433867</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manz</surname><given-names>M</given-names></name><name><surname>Reuter</surname><given-names>M</given-names></name><name><surname>Lauck</surname><given-names>G</given-names></name><name><surname>Omran</surname><given-names>H</given-names></name><name><surname>Jung</surname><given-names>W</given-names></name></person-group><article-title>A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction</article-title><source>Cardiology</source><year>2003</year><volume>100</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1159/000073933</pub-id><pub-id pub-id-type="pmid">14631136</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Lau</surname><given-names>CP</given-names></name></person-group><article-title>Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology</article-title><source>Drugs R D</source><year>2003</year><volume>4</volume><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.2165/00126839-200304020-00001</pub-id><pub-id pub-id-type="pmid">12718562</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>D</given-names></name><name><surname>De Santis</surname><given-names>V</given-names></name><name><surname>Guarracino</surname><given-names>F</given-names></name><name><surname>Fontana</surname><given-names>A</given-names></name><name><surname>Pellegrini</surname><given-names>F</given-names></name><name><surname>Tritapepe</surname><given-names>L</given-names></name></person-group><article-title>Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery</article-title><source>Clin Res Cardiol</source><year>2010</year><volume>99</volume><fpage>853</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1007/s00392-010-0208-9</pub-id><pub-id pub-id-type="pmid">20821020</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shchukin Iu</surname><given-names>V</given-names></name><name><surname>Vachev</surname><given-names>AN</given-names></name><name><surname>Surkova</surname><given-names>EA</given-names></name><name><surname>Germanov</surname><given-names>AV</given-names></name><name><surname>Golovin</surname><given-names>EA</given-names></name><name><surname>D'Iachkov</surname><given-names>VA</given-names></name></person-group><article-title>[The role of beta-adrenoblockers and If-inhibitor ivabradine in lowering of rate of development of cardiac complications after carotid endarterectomy]</article-title><source>Kardiologiia</source><year>2008</year><volume>48</volume><fpage>56</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">18537805</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name></person-group><article-title>Stabilization of atherosclerotic plaques: new mechanisms and clinical targets</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>1257</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1038/nm1102-1257</pub-id><pub-id pub-id-type="pmid">12411953</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFalls</surname><given-names>EO</given-names></name><name><surname>Ward</surname><given-names>HB</given-names></name><name><surname>Moritz</surname><given-names>TE</given-names></name><name><surname>Apple</surname><given-names>FS</given-names></name><name><surname>Goldman</surname><given-names>S</given-names></name><name><surname>Pierpont</surname><given-names>G</given-names></name><name><surname>Larsen</surname><given-names>GC</given-names></name><name><surname>Hattler</surname><given-names>B</given-names></name><name><surname>Shunk</surname><given-names>K</given-names></name><name><surname>Littooy</surname><given-names>F</given-names></name><name><surname>Santilli</surname><given-names>S</given-names></name><name><surname>Rapp</surname><given-names>J</given-names></name><name><surname>Thottapurathu</surname><given-names>L</given-names></name><name><surname>Krupski</surname><given-names>W</given-names></name><name><surname>Reda</surname><given-names>DJ</given-names></name><name><surname>Henderson</surname><given-names>WG</given-names></name></person-group><article-title>Predictors and outcomes of a perioperative myocardial infarction following elective vascular surgery in patients with documented coronary artery disease: results of the CARP trial</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehm620</pub-id><pub-id pub-id-type="pmid">18245121</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Thomas</surname><given-names>EJ</given-names></name><name><surname>Ludwig</surname><given-names>LE</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name><name><surname>Johnson</surname><given-names>PA</given-names></name><name><surname>Donaldson</surname><given-names>MC</given-names></name><name><surname>Cook</surname><given-names>EF</given-names></name><name><surname>Pedan</surname><given-names>A</given-names></name><name><surname>Kuntz</surname><given-names>KM</given-names></name><name><surname>Goldman</surname><given-names>L</given-names></name></person-group><article-title>Troponin T as a marker for myocardial ischemia in patients undergoing major noncardiac surgery</article-title><source>Am J Cardiol</source><year>1996</year><volume>77</volume><fpage>1031</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(96)00126-9</pub-id><pub-id pub-id-type="pmid">8644653</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breslow</surname><given-names>MJ</given-names></name><name><surname>Parker</surname><given-names>SD</given-names></name><name><surname>Frank</surname><given-names>SM</given-names></name><name><surname>Norris</surname><given-names>EJ</given-names></name><name><surname>Yates</surname><given-names>H</given-names></name><name><surname>Raff</surname><given-names>H</given-names></name><name><surname>Rock</surname><given-names>P</given-names></name><name><surname>Christopherson</surname><given-names>R</given-names></name><name><surname>Rosenfeld</surname><given-names>BA</given-names></name><name><surname>Beattie</surname><given-names>C</given-names></name></person-group><article-title>Determinants of catecholamine and cortisol responses to lower extremity revascularization. The PIRAT Study Group</article-title><source>Anesthesiology</source><year>1993</year><volume>79</volume><fpage>1202</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1097/00000542-199312000-00010</pub-id><pub-id pub-id-type="pmid">8267195</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sametz</surname><given-names>W</given-names></name><name><surname>Metzler</surname><given-names>H</given-names></name><name><surname>Gries</surname><given-names>M</given-names></name><name><surname>Porta</surname><given-names>S</given-names></name><name><surname>Sadjak</surname><given-names>A</given-names></name><name><surname>Supanz</surname><given-names>S</given-names></name><name><surname>Juan</surname><given-names>H</given-names></name></person-group><article-title>Perioperative catecholamine changes in cardiac risk patients</article-title><source>Eur J Clin Invest</source><year>1999</year><volume>29</volume><fpage>582</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2362.1999.00509.x</pub-id><pub-id pub-id-type="pmid">10411663</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chernow</surname><given-names>B</given-names></name><name><surname>Alexander</surname><given-names>HR</given-names></name><name><surname>Smallridge</surname><given-names>RC</given-names></name><name><surname>Thompson</surname><given-names>WR</given-names></name><name><surname>Cook</surname><given-names>D</given-names></name><name><surname>Beardsley</surname><given-names>D</given-names></name><name><surname>Fink</surname><given-names>MP</given-names></name><name><surname>Lake</surname><given-names>CR</given-names></name><name><surname>Fletcher</surname><given-names>JR</given-names></name></person-group><article-title>Hormonal responses to graded surgical stress</article-title><source>Arch Intern Med</source><year>1987</year><volume>147</volume><fpage>1273</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1001/archinte.1987.00370070087013</pub-id><pub-id pub-id-type="pmid">3606284</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>SD</given-names></name><name><surname>Breslow</surname><given-names>MJ</given-names></name><name><surname>Frank</surname><given-names>SM</given-names></name><name><surname>Rosenfeld</surname><given-names>BA</given-names></name><name><surname>Norris</surname><given-names>EJ</given-names></name><name><surname>Christopherson</surname><given-names>R</given-names></name><name><surname>Rock</surname><given-names>P</given-names></name><name><surname>Gottlieb</surname><given-names>SO</given-names></name><name><surname>Raff</surname><given-names>H</given-names></name><name><surname>Perler</surname><given-names>BA</given-names></name><name><surname>Williams</surname><given-names>GM</given-names></name><name><surname>Beattie</surname><given-names>C</given-names></name></person-group><article-title>Catecholamine and cortisol responses to lower extremity revascularization: correlation with outcome variables. Perioperative Ischemia Randomized Anesthesia Trial Study Group</article-title><source>Crit Care Med</source><year>1995</year><volume>23</volume><fpage>1954</fpage><lpage>1961</lpage><pub-id pub-id-type="doi">10.1097/00003246-199512000-00003</pub-id><pub-id pub-id-type="pmid">7497717</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>BA</given-names></name><name><surname>Faraday</surname><given-names>N</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Dorman</surname><given-names>T</given-names></name><name><surname>Clarkson</surname><given-names>K</given-names></name><name><surname>Siedler</surname><given-names>A</given-names></name><name><surname>Breslow</surname><given-names>MJ</given-names></name><name><surname>Bell</surname><given-names>W</given-names></name></person-group><article-title>Perioperative platelet reactivity and the effects of clonidine</article-title><source>Anesthesiology</source><year>1993</year><volume>79</volume><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1097/00000542-199308000-00010</pub-id><pub-id pub-id-type="pmid">8342838</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasceri</surname><given-names>V</given-names></name><name><surname>Patti</surname><given-names>G</given-names></name><name><surname>Nusca</surname><given-names>A</given-names></name><name><surname>Pristipino</surname><given-names>C</given-names></name><name><surname>Richichi</surname><given-names>G</given-names></name><name><surname>Di Sciascio</surname><given-names>G</given-names></name></person-group><article-title>Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000137828.06205.87</pub-id><pub-id pub-id-type="pmid">15277322</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briguori</surname><given-names>C</given-names></name><name><surname>Visconti</surname><given-names>G</given-names></name><name><surname>Focaccio</surname><given-names>A</given-names></name><name><surname>Golia</surname><given-names>B</given-names></name><name><surname>Chieffo</surname><given-names>A</given-names></name><name><surname>Castelli</surname><given-names>A</given-names></name><name><surname>Mussardo</surname><given-names>M</given-names></name><name><surname>Montorfano</surname><given-names>M</given-names></name><name><surname>Ricciardelli</surname><given-names>B</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name></person-group><article-title>Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>54</volume><fpage>2157</fpage><lpage>2163</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.07.005</pub-id><pub-id pub-id-type="pmid">19664895</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindenauer</surname><given-names>PK</given-names></name><name><surname>Pekow</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Gutierrez</surname><given-names>B</given-names></name><name><surname>Benjamin</surname><given-names>EM</given-names></name></person-group><article-title>Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>2092</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1001/jama.291.17.2092</pub-id><pub-id pub-id-type="pmid">15126437</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hindler</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>AD</given-names></name><name><surname>Samuels</surname><given-names>J</given-names></name><name><surname>Fulton</surname><given-names>S</given-names></name><name><surname>Collard</surname><given-names>CD</given-names></name><name><surname>Riedel</surname><given-names>B</given-names></name></person-group><article-title>Improved postoperative outcomes associated with preoperative statin therapy</article-title><source>Anesthesiology</source><year>2006</year><volume>105</volume><fpage>1260</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1097/00000542-200612000-00027</pub-id><pub-id pub-id-type="pmid">17122590</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Biomarkers in heart failure</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2148</fpage><lpage>2159</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0800239</pub-id><pub-id pub-id-type="pmid">18480207</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Leip</surname><given-names>EP</given-names></name><name><surname>Omland</surname><given-names>T</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name></person-group><article-title>Plasma natriuretic peptide levels and the risk of cardiovascular events and death</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>655</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa031994</pub-id><pub-id pub-id-type="pmid">14960742</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zethelius</surname><given-names>B</given-names></name><name><surname>Berglund</surname><given-names>L</given-names></name><name><surname>Sundstrom</surname><given-names>J</given-names></name><name><surname>Ingelsson</surname><given-names>E</given-names></name><name><surname>Basu</surname><given-names>S</given-names></name><name><surname>Larsson</surname><given-names>A</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>Arnlov</surname><given-names>J</given-names></name></person-group><article-title>Use of multiple biomarkers to improve the prediction of death from cardiovascular causes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2107</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0707064</pub-id><pub-id pub-id-type="pmid">18480203</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lemos</surname><given-names>JA</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>Bentley</surname><given-names>JH</given-names></name><name><surname>Omland</surname><given-names>T</given-names></name><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>McCabe</surname><given-names>CH</given-names></name><name><surname>Hall</surname><given-names>C</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>1014</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011053</pub-id><pub-id pub-id-type="pmid">11586953</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>de Lemos</surname><given-names>JA</given-names></name><name><surname>Blazing</surname><given-names>MA</given-names></name><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Murphy</surname><given-names>SA</given-names></name><name><surname>Jarolim</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>HD</given-names></name><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease</article-title><source>JAMA</source><year>2005</year><volume>294</volume><fpage>2866</fpage><lpage>2871</lpage><pub-id pub-id-type="doi">10.1001/jama.294.22.2866</pub-id><pub-id pub-id-type="pmid">16352794</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omland</surname><given-names>T</given-names></name><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Rice</surname><given-names>MM</given-names></name><name><surname>Hsia</surname><given-names>J</given-names></name><name><surname>Wergeland</surname><given-names>R</given-names></name><name><surname>Landaas</surname><given-names>S</given-names></name><name><surname>Rouleau</surname><given-names>JL</given-names></name><name><surname>Domanski</surname><given-names>MJ</given-names></name><name><surname>Hall</surname><given-names>C</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.03.038</pub-id><pub-id pub-id-type="pmid">17631211</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnabel</surname><given-names>RB</given-names></name><name><surname>Schulz</surname><given-names>A</given-names></name><name><surname>Messow</surname><given-names>CM</given-names></name><name><surname>Lubos</surname><given-names>E</given-names></name><name><surname>Wild</surname><given-names>PS</given-names></name><name><surname>Zeller</surname><given-names>T</given-names></name><name><surname>Sinning</surname><given-names>CR</given-names></name><name><surname>Rupprecht</surname><given-names>HJ</given-names></name><name><surname>Bickel</surname><given-names>C</given-names></name><name><surname>Peetz</surname><given-names>D</given-names></name><name><surname>Cambien</surname><given-names>F</given-names></name><name><surname>Kempf</surname><given-names>T</given-names></name><name><surname>Wollert</surname><given-names>KC</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Lackner</surname><given-names>KJ</given-names></name><name><surname>Munzel</surname><given-names>TF</given-names></name><name><surname>Tiret</surname><given-names>L</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Blankenberg</surname><given-names>S</given-names></name></person-group><article-title>Multiple marker approach to risk stratification in patients with stable coronary artery disease</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><fpage>3024</fpage><lpage>3031</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehq322</pub-id><pub-id pub-id-type="pmid">20852293</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>CP</given-names></name><name><surname>Ryan</surname><given-names>JE</given-names></name><name><surname>van Gaal</surname><given-names>WJ</given-names></name><name><surname>Lam</surname><given-names>QT</given-names></name><name><surname>Sinnappu</surname><given-names>RN</given-names></name><name><surname>Burrell</surname><given-names>LM</given-names></name><name><surname>Savige</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>WK</given-names></name></person-group><article-title>Usefulness of N-terminal pro-brain natriuretic peptide to predict postoperative cardiac complications and long-term mortality after emergency lower limb orthopedic surgery</article-title><source>Am J Cardiol</source><year>2010</year><volume>106</volume><fpage>865</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2010.05.012</pub-id><pub-id pub-id-type="pmid">20816130</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>de Lemos</surname><given-names>JA</given-names></name><name><surname>Omland</surname><given-names>T</given-names></name><name><surname>Sloan</surname><given-names>S</given-names></name><name><surname>Jarolim</surname><given-names>P</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease</article-title><source>Circulation</source><year>2012</year><volume>125</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.063842</pub-id><pub-id pub-id-type="pmid">22179538</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>ER</given-names></name><name><surname>Gardner</surname><given-names>DG</given-names></name><name><surname>Samson</surname><given-names>WK</given-names></name></person-group><article-title>Natriuretic peptides</article-title><source>N Engl J Med</source><year>1998</year><volume>339</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1056/NEJM199807303390507</pub-id><pub-id pub-id-type="pmid">9682046</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunton</surname><given-names>DC</given-names></name><name><surname>Petrie</surname><given-names>MC</given-names></name><name><surname>Hillier</surname><given-names>C</given-names></name><name><surname>Johnston</surname><given-names>F</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name></person-group><article-title>The clinical relevance of adrenomedullin: a promising profile?</article-title><source>Pharmacol Ther</source><year>2004</year><volume>103</volume><fpage>179</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2004.07.002</pub-id><pub-id pub-id-type="pmid">15464589</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jougasaki</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>TL</given-names></name><name><surname>Borgeson</surname><given-names>DD</given-names></name><name><surname>Luchner</surname><given-names>A</given-names></name><name><surname>Redfield</surname><given-names>MM</given-names></name><name><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group><article-title>Adrenomedullin in experimental congestive heart failure: cardiorenal activation</article-title><source>Am J Physiol</source><year>1997</year><volume>273</volume><fpage>R1392</fpage><lpage>R1399</lpage><pub-id pub-id-type="pmid">9362304</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spieker</surname><given-names>LE</given-names></name><name><surname>Noll</surname><given-names>G</given-names></name><name><surname>Ruschitzka</surname><given-names>FT</given-names></name><name><surname>Luscher</surname><given-names>TF</given-names></name></person-group><article-title>Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><fpage>1493</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01210-4</pub-id><pub-id pub-id-type="pmid">11345356</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moertl</surname><given-names>D</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name><name><surname>Struck</surname><given-names>J</given-names></name><name><surname>Gleiss</surname><given-names>A</given-names></name><name><surname>Hammer</surname><given-names>A</given-names></name><name><surname>Morgenthaler</surname><given-names>NG</given-names></name><name><surname>Bergmann</surname><given-names>A</given-names></name><name><surname>Huelsmann</surname><given-names>M</given-names></name><name><surname>Pacher</surname><given-names>R</given-names></name></person-group><article-title>Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><fpage>1783</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.01.057</pub-id><pub-id pub-id-type="pmid">19422985</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Haehling</surname><given-names>S</given-names></name><name><surname>Filippatos</surname><given-names>GS</given-names></name><name><surname>Papassotiriou</surname><given-names>J</given-names></name><name><surname>Cicoira</surname><given-names>M</given-names></name><name><surname>Jankowska</surname><given-names>EA</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Rozentryt</surname><given-names>P</given-names></name><name><surname>Vassanelli</surname><given-names>C</given-names></name><name><surname>Struck</surname><given-names>J</given-names></name><name><surname>Banasiak</surname><given-names>W</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Kremastinos</surname><given-names>D</given-names></name><name><surname>Bergmann</surname><given-names>A</given-names></name><name><surname>Morgenthaler</surname><given-names>NG</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name></person-group><article-title>Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure</article-title><source>Eur J Heart Fail</source><year>2010</year><volume>12</volume><fpage>484</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfq031</pub-id><pub-id pub-id-type="pmid">20215339</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankowska</surname><given-names>EA</given-names></name><name><surname>Filippatos</surname><given-names>GS</given-names></name><name><surname>von Haehling</surname><given-names>S</given-names></name><name><surname>Papassotiriou</surname><given-names>J</given-names></name><name><surname>Morgenthaler</surname><given-names>NG</given-names></name><name><surname>Cicoira</surname><given-names>M</given-names></name><name><surname>Schefold</surname><given-names>JC</given-names></name><name><surname>Rozentryt</surname><given-names>P</given-names></name><name><surname>Ponikowska</surname><given-names>B</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Banasiak</surname><given-names>W</given-names></name><name><surname>Hartmann</surname><given-names>O</given-names></name><name><surname>Struck</surname><given-names>J</given-names></name><name><surname>Bergmann</surname><given-names>A</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name></person-group><article-title>Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e14506</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0014506</pub-id><pub-id pub-id-type="pmid">21264211</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ala-Kopsala</surname><given-names>M</given-names></name><name><surname>Magga</surname><given-names>J</given-names></name><name><surname>Peuhkurinen</surname><given-names>K</given-names></name><name><surname>Leipala</surname><given-names>J</given-names></name><name><surname>Ruskoaho</surname><given-names>H</given-names></name><name><surname>Leppaluoto</surname><given-names>J</given-names></name><name><surname>Vuolteenaho</surname><given-names>O</given-names></name></person-group><article-title>Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides</article-title><source>Clin Chem</source><year>2004</year><volume>50</volume><fpage>1576</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2004.032490</pub-id><pub-id pub-id-type="pmid">15265819</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>SK</given-names></name><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Benessiano</surname><given-names>J</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>AG</given-names></name><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Schwartz</surname><given-names>GG</given-names></name><name><surname>Tsimikas</surname><given-names>S</given-names></name></person-group><article-title>Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes</article-title><source>Circulation</source><year>2012</year><volume>125</volume><fpage>757</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.063487</pub-id><pub-id pub-id-type="pmid">22230483</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillarisett</surname><given-names>S</given-names></name><name><surname>Alexander</surname><given-names>CW</given-names></name><name><surname>Saxena</surname><given-names>U</given-names></name></person-group><article-title>Atherosclerosis &#x02013; new targets and therapeutics</article-title><source>Curr Med Chem Cardiovasc Hematol Agents</source><year>2004</year><volume>2</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.2174/1568016043356246</pub-id><pub-id pub-id-type="pmid">15320783</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Willerson</surname><given-names>JT</given-names></name></person-group><article-title>Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature</article-title><source>Tex Heart Inst J</source><year>2010</year><volume>37</volume><issue>1</issue><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">20200624</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tselepis</surname><given-names>AD</given-names></name><name><surname>John</surname><given-names>CM</given-names></name></person-group><article-title>Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating</article-title><source>Atheroscler Suppl</source><year>2002</year><volume>3</volume><issue>4</issue><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/S1567-5688(02)00045-4</pub-id><pub-id pub-id-type="pmid">12573364</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Lambeau</surname><given-names>G</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name></person-group><article-title>Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>2183</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.936393</pub-id><pub-id pub-id-type="pmid">21098459</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nijmeijer</surname><given-names>R</given-names></name><name><surname>Meuwissen</surname><given-names>M</given-names></name><name><surname>Krijnen</surname><given-names>PA</given-names></name><name><surname>van der Wal</surname><given-names>A</given-names></name><name><surname>Piek</surname><given-names>JJ</given-names></name><name><surname>Visser</surname><given-names>CA</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Niessen</surname><given-names>HW</given-names></name></person-group><article-title>Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction</article-title><source>Eur J Clin Invest</source><year>2008</year><volume>38</volume><issue>4</issue><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2008.01933.x</pub-id><pub-id pub-id-type="pmid">18339001</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kugiyama</surname><given-names>K</given-names></name><name><surname>Ota</surname><given-names>Y</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Kawano</surname><given-names>H</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name><name><surname>Soejima</surname><given-names>H</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Takazoe</surname><given-names>K</given-names></name><name><surname>Yasue</surname><given-names>H</given-names></name></person-group><article-title>Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris</article-title><source>Am J Cardiol</source><year>2000</year><volume>86</volume><issue>7</issue><fpage>718</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(00)01069-9</pub-id><pub-id pub-id-type="pmid">11018189</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kugiyama</surname><given-names>K</given-names></name><name><surname>Ota</surname><given-names>Y</given-names></name><name><surname>Takazoe</surname><given-names>K</given-names></name><name><surname>Moriyama</surname><given-names>Y</given-names></name><name><surname>Kawano</surname><given-names>H</given-names></name><name><surname>Miyao</surname><given-names>Y</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Soejima</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Yasue</surname><given-names>H</given-names></name></person-group><article-title>Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease</article-title><source>Circulation</source><year>1999</year><volume>100</volume><issue>12</issue><fpage>1280</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.100.12.1280</pub-id><pub-id pub-id-type="pmid">10491371</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Tsai</surname><given-names>WC</given-names></name><name><surname>Chao</surname><given-names>TH</given-names></name><name><surname>Tsai</surname><given-names>LM</given-names></name><name><surname>Wu</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name></person-group><article-title>Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><issue>20</issue><fpage>1824</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1016/j.ehj.2003.07.003</pub-id><pub-id pub-id-type="pmid">14563341</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Benessiano</surname><given-names>J</given-names></name><name><surname>Simon</surname><given-names>T</given-names></name><name><surname>Ederhy</surname><given-names>S</given-names></name><name><surname>Sebella-Arguelles</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>A</given-names></name><name><surname>Huart</surname><given-names>V</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><name><surname>Boekholdt</surname><given-names>SM</given-names></name></person-group><article-title>Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-NORFOLK study</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2007</year><volume>27</volume><issue>5</issue><fpage>1177</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.107.139352</pub-id><pub-id pub-id-type="pmid">17303774</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Vossen</surname><given-names>CY</given-names></name><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Benessiano</surname><given-names>J</given-names></name><name><surname>Rothenbacher</surname><given-names>D</given-names></name></person-group><article-title>Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><issue>22</issue><fpage>2742</fpage><lpage>2748</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehp302</pub-id><pub-id pub-id-type="pmid">19666896</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggen</surname><given-names>DA</given-names></name><name><surname>Strong</surname><given-names>JP</given-names></name><name><surname>McGill</surname><given-names>HC</given-names><suffix>Jr</suffix></name></person-group><article-title>Coronary calcification. Relationship to clinically significant coronary lesions and race, sex, and topographic distribution</article-title><source>Circulation</source><year>1965</year><volume>32</volume><fpage>948</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.32.6.948</pub-id><pub-id pub-id-type="pmid">5845254</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoff</surname><given-names>JA</given-names></name><name><surname>Chomka</surname><given-names>EV</given-names></name><name><surname>Krainik</surname><given-names>AJ</given-names></name><name><surname>Daviglus</surname><given-names>M</given-names></name><name><surname>Rich</surname><given-names>S</given-names></name><name><surname>Kondos</surname><given-names>GT</given-names></name></person-group><article-title>Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults</article-title><source>Am J Cardiol</source><year>2001</year><volume>87</volume><fpage>1335</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(01)01548-X</pub-id><pub-id pub-id-type="pmid">11397349</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keelan</surname><given-names>PC</given-names></name><name><surname>Bielak</surname><given-names>LF</given-names></name><name><surname>Ashai</surname><given-names>K</given-names></name><name><surname>Jamjoum</surname><given-names>LS</given-names></name><name><surname>Denktas</surname><given-names>AE</given-names></name><name><surname>Rumberger</surname><given-names>JA</given-names></name><name><surname>Sheedy</surname><given-names>IP</given-names></name><name><surname>Peyser</surname><given-names>PA</given-names></name><name><surname>Schwartz</surname><given-names>RS</given-names></name></person-group><article-title>Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography</article-title><source>Circulation</source><year>2001</year><volume>104</volume><fpage>412</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1161/hc2901.093112</pub-id><pub-id pub-id-type="pmid">11468202</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>ND</given-names></name><name><surname>Hsu</surname><given-names>JC</given-names></name><name><surname>Detrano</surname><given-names>RC</given-names></name><name><surname>Diamond</surname><given-names>G</given-names></name><name><surname>Eisenberg</surname><given-names>H</given-names></name><name><surname>Gardin</surname><given-names>JM</given-names></name></person-group><article-title>Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events</article-title><source>Am J Cardiol</source><year>2000</year><volume>86</volume><fpage>495</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(00)01000-6</pub-id><pub-id pub-id-type="pmid">11009264</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>JJ</given-names></name><name><surname>Crouse</surname><given-names>JR</given-names><suffix>3rd</suffix></name><name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name><name><surname>D'Agostino</surname><given-names>RB</given-names><suffix>Jr</suffix></name><name><surname>Peterson</surname><given-names>NP</given-names></name><name><surname>Burke</surname><given-names>GL</given-names></name></person-group><article-title>Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT</article-title><source>AJR Am J Roentgenol</source><year>2000</year><volume>174</volume><fpage>915</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.2214/ajr.174.4.1740915</pub-id><pub-id pub-id-type="pmid">10749222</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callister</surname><given-names>TQ</given-names></name><name><surname>Cooil</surname><given-names>B</given-names></name><name><surname>Raya</surname><given-names>SP</given-names></name><name><surname>Lippolis</surname><given-names>NJ</given-names></name><name><surname>Russo</surname><given-names>DJ</given-names></name><name><surname>Raggi</surname><given-names>P</given-names></name></person-group><article-title>Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method</article-title><source>Radiology</source><year>1998</year><volume>208</volume><fpage>807</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1148/radiology.208.3.9722864</pub-id><pub-id pub-id-type="pmid">9722864</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Bijl</surname><given-names>N</given-names></name><name><surname>de Bruin</surname><given-names>PW</given-names></name><name><surname>Geleijns</surname><given-names>J</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Schuijf</surname><given-names>JD</given-names></name><name><surname>de Roos</surname><given-names>A</given-names></name><name><surname>Kroft</surname><given-names>LJM</given-names></name></person-group><article-title>Assessment of coronary artery calcium by using volumetric 320-row multi-detector computed tomography: comparison of 0.5&#x000a0;mm with 3.0&#x000a0;mm slice reconstructions</article-title><source>Int J Cardiovasc Imaging</source><year>2010</year><volume>26</volume><fpage>473</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1007/s10554-010-9581-8</pub-id><pub-id pub-id-type="pmid">20072817</pub-id></element-citation></ref></ref-list></back></article>